Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Frank Bennett

Showing results (11-20 of 169) with videos related to

Pageof 17
Sort By:
Annual Review of Neuroscience|July 9, 2019
Antisense Oligonucleotide Therapies for Neurodegenerative DiseasesC Frank Bennett, Adrian R Krainer, Don W Cleveland
The New England Journal of Medicine|September 19, 2019
Targeting Huntingtin in Patients with Huntington's Disease. ReplySarah J Tabrizi, Anne V Smith, C Frank Bennett
Advanced Drug Delivery Reviews|February 11, 2015
Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotidesRichard S Geary, Daniel Norris, Rosie Yu, et al.
The Journal of Cell Biology|October 3, 2012
Antisense-based therapy for the treatment of spinal muscular atrophyFrank Rigo, Yimin Hua, Adrian R Krainer, et al.
Oligonucleotides|July 2, 2005
Induction of toll-like receptors and NALP/PAN/PYPAF family members by modified oligonucleotides in lung epithelial carcinoma cellsDenis Drygin, Seongjoon Koo, Ranjan Perera, et al.
Molecular Therapy. Nucleic Acids|April 10, 2019
Delivery of GalNAc-Conjugated Splice-Switching ASOs to Non-hepatic Cells through Ectopic Expression of Asialoglycoprotein ReceptorJuergen Scharner, Sabrina Qi, Frank Rigo, et al.
Cell Metabolism|February 7, 2019
RNA-Targeted TherapeuticsStanley T Crooke, Joseph L Witztum, C Frank Bennett, et al.
Nucleic Acids Research|March 5, 2014
Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotidesAmanda J Ward, Michaela Norrbom, Seung Chun, et al.
Trends in Molecular Medicine|October 3, 2012
Antisense oligonucleotide therapeutics for inherited neurodegenerative diseasesAmber L Southwell, Niels H Skotte, C Frank Bennett, et al.
Cell Metabolism|April 5, 2018
RNA-Targeted TherapeuticsStanley T Crooke, Joseph L Witztum, C Frank Bennett, et al.
Pageof 17

Showing results (11-20 of 169) with videos related to

Sort By:
Pageof 17
Annual Review of Neuroscience|July 9, 2019
Antisense Oligonucleotide Therapies for Neurodegenerative DiseasesC Frank Bennett, Adrian R Krainer, Don W Cleveland
The New England Journal of Medicine|September 19, 2019
Targeting Huntingtin in Patients with Huntington's Disease. ReplySarah J Tabrizi, Anne V Smith, C Frank Bennett
Advanced Drug Delivery Reviews|February 11, 2015
Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotidesRichard S Geary, Daniel Norris, Rosie Yu, et al.
The Journal of Cell Biology|October 3, 2012
Antisense-based therapy for the treatment of spinal muscular atrophyFrank Rigo, Yimin Hua, Adrian R Krainer, et al.
Oligonucleotides|July 2, 2005
Induction of toll-like receptors and NALP/PAN/PYPAF family members by modified oligonucleotides in lung epithelial carcinoma cellsDenis Drygin, Seongjoon Koo, Ranjan Perera, et al.
Molecular Therapy. Nucleic Acids|April 10, 2019
Delivery of GalNAc-Conjugated Splice-Switching ASOs to Non-hepatic Cells through Ectopic Expression of Asialoglycoprotein ReceptorJuergen Scharner, Sabrina Qi, Frank Rigo, et al.
Cell Metabolism|February 7, 2019
RNA-Targeted TherapeuticsStanley T Crooke, Joseph L Witztum, C Frank Bennett, et al.
Nucleic Acids Research|March 5, 2014
Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotidesAmanda J Ward, Michaela Norrbom, Seung Chun, et al.
Trends in Molecular Medicine|October 3, 2012
Antisense oligonucleotide therapeutics for inherited neurodegenerative diseasesAmber L Southwell, Niels H Skotte, C Frank Bennett, et al.
Cell Metabolism|April 5, 2018
RNA-Targeted TherapeuticsStanley T Crooke, Joseph L Witztum, C Frank Bennett, et al.
Pageof 17